Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage

Transfusion

Volumn 48, Issue 7, 2008, Pages 1469-1477

  Skripchenko, Audrey ^a,b   Kurtz, James ^a   Moroff, Gary ^a   Wagner, Stephen J ^a   Skripchenko, Andrey ^a  

^a HOLLAND LABORATORY   (United States)

^b AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD40 LIGAND; PADGEM PROTEIN; THROMBOCYTE CONCENTRATE;

APHERESIS; ARTICLE; BLOOD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; PLASMA; PROTEIN EXPRESSION; SEDIMENTATION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE PRESERVATION; THROMBOCYTE RICH PLASMA; BLOOD STORAGE; CYTOLOGY; HUMAN; KINETICS; METABOLISM; METHODOLOGY;

BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; BLOOD PRESERVATION; CD40 LIGAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; KINETICS; P-SELECTIN; PLATELET ACTIVATION;

EID: 52049096653     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01733.x     Document Type: Article

References (42)

1. Akay OM, Gunduz E, Basyigit H, Gulbas Z. Platelet function testing during 5-day storage of single and random donor plateletpheresis. Transfus Apher Sci 2007;36:285-9.
2. Fijnheer R, Modderman PW, Veldman H, Ouwehand WH, Nieuwenhuis DR, De Korte D. Detection of platelet activation with monoclonal antibodies and flow cytometry. Transfusion 1990;30:20-5.
3. Matsubayashi H, Weidner J, Miraglia CC, McIntyre J. Platelet membrane early activation markers during prolonged storage. Thromb Res 1999;93:151-60.
4. Heddle NM, Barty RL, Sigouin CS, Boye DM, Nelson EJ, Blajchman MA, Kelton JG. In vitro evaluation of prestorage pooled leukoreduced whole blood-derived platelets stored for up to 7 days. Transfusion 2005;45:904-10.
5. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-82.
6. Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood 1998;92:4446-52.
7. Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991;31:409-14.
8. Vetlesen A, Mirlashari MR, Ezligini F, Kjeldsen-Kragh J. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system. Transfusion 2007;47:126-32.
9. Holme S. Storage and quality assessment of platelets. Vox Sang 1998;74:207-16.
10. Metcalfe P, Williamson LM, Reutelingsperger CP, Swann I, Ouwehand WH, Goodall AH. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997;98:86-95.
11. Snyder EL, Hezzey A, Katz AJ, Bock J. Occurrence of the platelet reaction during preparation and storage of platelet concentrates. Vox Sang 1981;41:172-7.
12. Snyder EL. Release of beta-thromboglobulin during storage of platelet concentrates. Vox Sang 1981;40:115-6.
13. Fijnheer R, Modderman PW, Veldman H, Ouwehand WH, Nieuwenhuis DR, De Korte D. Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion 1990;30: 20-5.
14. Rinder HM, Snyder EL. Activation of platelet concentrate during preparation and storage. Blood Cells 1992;18:445- 56.
15. Rinder HM, Snyder EL, Bonan JL, Napychank PA, Malkus H, Smith BR. Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and beta-thromboglobulin release. Transfusion 1993;33:25-9.
16. Kostelijk EH, Fijnheer R, Nieuwenhuis HK, Gouwerok CW, de Korte D. Soluble p-selectin as parameter for platelet activation during storage. Thromb Haemost 1996;76: 1086-9.
17. Kyrle PA, Hron G, Eichinger S, Wagner O. Circulating p-selectin and the risk of recurrent venous thromboembolism. Thromb Haemost 2007;97:880-3.
18. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31:381-92.
19. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92:1041-8.
20. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047-54.
21. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytok- ines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 1995;92:4342-6.
22. van Kooten C, Gaillard C, Galizzi JP, Hermann P, Fossiez F, Banchereau J, Blanchard D. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol 1994;24:787-92.
23. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by ligand for CD40. J Exp Med 1993;178:669-74.
24. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180: 1263-72.
25. Spriggs MK, Armitage RJ, Strockine L, Clifford KN, Macduff BM, Sato TA, Maliszewski CR, Fanslow WC. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992;176:1543-50.
26. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
27. Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001;357:2023-4.
28. Blumberg N, Gattings KF, Turner C, Heal JM, Phipps RP. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006;46:1813-21.
29. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, Gettings KF, McLaughlin NJ, Silliman CC. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006;108:2455-62.
30. Danese S, Fiocchi C. Platelet activation and the CD40/ CD40 ligand pathway: mechanism and implications for human disease. Crit Rev Immunol 2005;25:103-21.
31. Danese S, Scaldaferri F, Vetrano S, Stefanelli T, Graziani C, Repici A, Ricci R, Straface G, Sgambato A, Malesci A, Fiocchi C, Rutella S. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 2007;56: 1248-56.
32. Tousoulis D, Antoniades C, Nikolopoulou A, Koniari K, Vasiliadou C, Marinou K, Koumallos N, Papageorgiou N, Stefanadi E, Siasos G, Stefanadis C. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007;37: 623-8.
33. Martino F, Pignatelli P, Martino E, Morrone F, Carnevale R, Di Santo S, Martini A, Loffredo L, Violi F. Early increase of oxidative stress and soluble CD40L in children with hypercholesterolemia. J Am Coll Cardiol 2007;49:1974-81.
34. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 2006;26:165-71.
35. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774-9.
36. Varo N, Libby P, Nuzzo R, Italiano J, Doria A, Schonbeck U. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2005;2:81-7.
37. Kaufman J, Spinelli SL, Schultz E, Blumberg N, Phipps RP. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost 2007;5:788-96.
38. Fijnheer R, Pietersz RN, De Korte D, Gouwerok CW, Dekker WJ, Reesink HW, Roos D. Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion 1990;30:634-8.
39. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G, Ambrogi V, Spila A, Palmirotta R, D'Alessandro R, Davi G, Guadagni F, Ferroni P. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004;10:610-4.
40. Barnard MR, MacGregor H, Mercier R, Ragno G, Pivacek LE, Hechtman HB, Michelson AD, Valeri CR. Platelet surface p-selectin, platelet-granulocyte heterotypic aggregates, and plasma p-selectin during plateletapheresis. Transfusion 1999;39:735-41.
41. Holme S, Sweeney JD, Sawyer S, Elfath MD. The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997;37:12-7.
42. Herman A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001;12:74-82.